Typical examples include combining the PARPi olaparib with the anti‐angiogenic antibody bevacizumab to enhance tumour sensitivity to PARP inhibition,32 and pairing PARPis with agents targeting other SL‐related genes, such as WEE1, ATR or CHK1 inhibitors. This evidence concerns the gene ATR and neoplasm.